Citigroup downgrades Pharmion Corp (Nasdaq: PHRM) from Buy to Hold, but increases price target to $72. Citigroup analyst cites ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE